Gilead Sciences, Inc. GILD Archived
-7.83%This entry is more than 3 months old and has been archived. Prices reflect the last update.
✅ Key Summary
Gilead Sciences, Inc. focuses on antiviral drugs, particularly for HIV and hepatitis. The company has shown robust financial performance and a solid product pipeline that supports its valuation. Recent stock movements reflect investor confidence in its growth prospects.
🏢 Company Overview
Gilead Sciences, Inc. specializes in the development of antiviral medications, especially for HIV, hepatitis B, hepatitis C, and influenza. The company has reported strong earnings in its recent quarterly results, driven by increased demand for its flagship products. Gilead's innovative research pipeline is positioned to address unmet medical needs, potentially leading to new revenue streams. The stock has shown resilience in the market, with a current valuation that reflects its growth potential in the biotech sector. Additionally, Gilead's strategic partnerships and acquisitions have strengthened its competitive advantage. Investors are optimistic about the company's future, particularly with its advancements in therapies for chronic diseases. The stock price has fluctuated, but overall trends indicate a positive outlook. Gilead's market capitalization underscores its established presence in the industry.
📰 Related News
-
Gilead Announces Positive Phase 3 Trial Results for HIV TreatmentPositive news could boost investor confidence and stock price.
-
Gilead's New Drug Approval Expected Next QuarterPotential approval may lead to increased revenue forecasts.
-
Gilead Faces Lawsuit Over Patent DisputesLegal challenges may create short-term volatility in stock performance.
🏭 Competitor Comparison
-
AbbVie Inc. ABBVAbbVie focuses on immunology and oncology, providing diversification not present in Gilead's portfolio.
-
Bristol Myers Squibb Company BMYBristol Myers Squibb has a broader range of therapeutic areas, while Gilead specializes in antiviral treatments.
-
Vertex Pharmaceuticals Incorporated VRTXVertex is heavily focused on cystic fibrosis treatments, differing from Gilead's antiviral emphasis.
📅 Gilead Sciences, Inc. discovery history
This stock has been discovered 6 times.
| Discovered | Discovery price | Current price | Return |
|---|---|---|---|
| Sep 17, 2026 | $150.89 | $168.08 | +11.39% |
| Aug 12, 2026 | $135.87 | $170.87 | +25.76% |
| May 6, 2026 | $136.30 | $135.25 | -0.77% |
| Apr 1, 2026 | $140.30 | $126.34 | -9.95% |
| Dec 24, 2025 | $125.67 | $138.11 | +9.90% |